Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9309245	ENTASIS THERAP	Beta-lactamase inhibitor compounds	Apr, 2033 (8 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9623014	ENTASIS THERAP	β-lactamase inhibitor compounds	Apr, 2033 (8 years from now)
US9968593	ENTASIS THERAP	Combination therapy for treatment of resistant bacterial infections	Nov, 2035 (11 years from now)
US10376499	ENTASIS THERAP	Combination therapy for treatment of resistant bacterial infections	Nov, 2035 (11 years from now)

Xacduro (Copackaged) is owned by Entasis Therap.

Xacduro (Copackaged) contains Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium.

Xacduro (Copackaged) has a total of 4 drug patents out of which 0 drug patents have expired.

Xacduro (Copackaged) was authorised for market use on 23 May, 2023.

Xacduro (Copackaged) is available in powder;intravenous dosage forms.

Xacduro (Copackaged) can be used as treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp).

Drug patent challenges can be filed against Xacduro (Copackaged) from 23 May, 2032.

The generics of Xacduro (Copackaged) are possible to be released after 17 November, 2035.

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 23, 2028
Generating Antibiotic Incentives Now(GAIN)	May 23, 2033

NCE-1 date: 23 May, 2032

Market Authorisation Date: 23 May, 2023

Treatment: Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp)

Dosage: POWDER;INTRAVENOUS

Xacduro (copackaged) patents expiration